Screener
McKesson MCK Oncology & Multispecialty — Restructuring Reserve
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:RestructuringReserve.
The source filing: McKesson’s 10-K, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal year
- FY2026
- Accession
- 0000927653-26-000069
| (In millions) | North American Pharmaceutical | Oncology & Multispecialty | Prescription Technology Solutions | Medical-Surgical Solutions | Corporate & Other | Total |
|---|---|---|---|---|---|---|
| Balance, March 31, 2024 (1) | $23 | $3 | $5 | $1 | $23 | $55 |
| Restructuring, impairment, and related charges, net | 59 | 1 | 12 | 204 | 68 | 344 |
| Non-cash charges | (58) | (1) | (9) | (14) | (16) | (98) |
| Cash payments | (8) | (2) | (4) | (99) | (51) | (164) |
| Other (2) | (5) | (1) | (3) | (2) | — | (11) |
| Balance, March 31, 2025 (3) | 11 | — | 1 | 90 | 24 | 126 |
| Restructuring, impairment, and related charges, net | 24 | — | 20 | 43 | 158 | 245 |
| Non-cash charges | (12) | — | (17) | 8 | (8) | (29) |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is McKesson's oncology & multispecialty — restructuring reserve?
- McKesson (MCK) reported oncology & multispecialty — restructuring reserve of $0 in Q1 2026.
- What does oncology & multispecialty — restructuring reserve mean?
- The total accrued liability set aside for future costs related to organizational restructuring, such as severance, facility closures, or contract terminations. This represents the company's commitment to future efficiency-driven changes within the segment.
Ask your AI about McKesson's oncology & multispecialty — restructuring reserve.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude